With Covid-19 vaccine in limbo, China's Fosun inks $628M deal for a Prevnar 13 rival
Fosun Pharma, BioNTech’s partner for its Covid-19 vaccine in China, has its sights set on another enormous vaccine market.
The Shanghai-based company has bought a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
